Switching Antipsychotic Medications: General Recommendations and Switching to Amisulpride

References

• Kerwin R, Taylor D. New antipsychotics: a review of their current status and clinical potential. CNS Drugs 1996;1:71–82
   Google Scholar
• Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol 1995;10:207–13
   PubMed Web of Science ®Google Scholar
• Kopelowicz A, Zarate R, Tripodis K, Gonzalez V, sMintz J. Differential efficacy of olanzapine for deficit and nondeficit negative symptoms in schizophrenia Am J Psychiatry 2000;157:987–93
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Engel RR, Kissling W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180–90
   PubMed Web of Science ®Google Scholar
• Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther 1997;280: 73–82
   Google Scholar
• Borison RL, Consensus Study Group on Risperidone Dosing. Changing antipsychotic medication: guidelines on the transition to treatment with risperidone. Clin Ther 1996;18:592–607
   Google Scholar
• Kirov GK, Murray RM, Seth RV, Feeney S, Risperidone Switching Study Group. Observations on switching patients with schizophrenia to risperidone treatment. Acta Psychiatr Scand 1997;95:439–43
   Google Scholar
• Henderson DC, Nasrallah RA, Goff DC. Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy and predictors of response. J Clin Psychiatry 1998;59:585–8
   PubMed Web of Science ®Google Scholar
• Revicki DA. Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opin Investig Drugs 2001;2:110–17
   PubMedGoogle Scholar
• Keks NA, Copolov DL, Burrows D. Discontinuing antipsychotic therapy: a practical guide. CNS Drugs 1995;4:351–6
   Web of Science ®Google Scholar
• Lieberman J. Cholinergic rebound in neuroleptic withdrawal syndromes. Psychosomatics 1981;22:253–4
   PubMed Web of Science ®Google Scholar
• Luchins DJ, Freed WJ, Wyatt RJ. The role of cholinergic supersensitivity in the medical symptoms associated with withdrawal of antipsychotic drugs. Am J Psychiatry 1980;1371–95
   Google Scholar
• Wyatt RJ. Risks of withdrawing antipsychotic medications. Arch Gen Psychiatry 1995;52:205–8
   PubMed Web of Science ®Google Scholar
• Dixon L, Thaker G, Conley R, Ross D, Cascella N, Tamminga C. Changes in psychopathology and dyskinesia after neuroleptic withdrawal in a double-blind design. Schizophr Res 1993;10:267–71
   PubMed Web of Science ®Google Scholar
• Glazer WM, Bowers Jr MB, Charney DS, Heninger GR. The effect of neuroleptic discontinuation on psychopathology, involuntary movements and biochemical measures in patients with persistent tardive dyskinesia. Biol Psychiatry 1989;26:224–33
   PubMed Web of Science ®Google Scholar
• Dufresne RL, Wagner RL. Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive dyskinesia. J Clin Psychiatry 1988;49:435–8
   PubMed Web of Science ®Google Scholar
• Lang AE. Withdrawal akathisia: case report and a proposed classification of chronic akathisia. Mov Disord 1994;9:188–92
   PubMed Web of Science ®Google Scholar
• Radford J, Brown T, Borison R. Unexpected dystonia while changing from clozapine to risperidone. J Clin Psychopharmacol 1995;15:225–6
   PubMed Web of Science ®Google Scholar
• Simpson G, Kunz-Batholini E. Relationship of tolerance, behavior and phenothiazine produced extrapyramidal system disturbance. Dis Nerv Syst 1968;29:269–74
   PubMedGoogle Scholar
• Nelli AC, Yarden PE, Guazelli M, Feinberg I. Parkinsonism following neuroleptic withdrawal [letter]. Arch Gen Psychiatry 1989;46:383–4
   PubMed Web of Science ®Google Scholar
• Spivak B, Weizman A, Wolovick L, Hermesh H, Tyano S, Munitz H. Neuroleptic malignant syndrome during abrupt reduction of neuroleptic treatment. Acta Psychiatr Scand 1990;81:168–9
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Salz BL, et al. Clozapine-induced agranulocytosis: non-cross-reactivity with other psychotropic drugs. J Clin Psychiatry 1988;49:271–7
   PubMed Web of Science ®Google Scholar
• NIMH Activities. Clinical implications of clozapine discontinuation: report of an NIMH workshop. Schizophrenia Bull 1995;21:333–8
   PubMed Web of Science ®Google Scholar
• Taylor D. Pharmacokinetic interactions involving clozapine. Br J Psychiatry 1997;171:109–12
   PubMed Web of Science ®Google Scholar
• Committee on Safety of Medicines. UK Medicines Control Agency. Drug-induced neutropenia and agranulocytosis. Curr Prob 1993;10:10–11
   Google Scholar
• Chong SA, Tan CH, Lee HS. Atrial ectopics with clozapinerisperidone combination [letter]. J Clin Psychopharmacol 1987;17:130–1
   Google Scholar
• Naranjo CA, Sproule BA, Knocke DM. Metabolic interactions of central nervous system medications and selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 1999;14(Suppl 2):535–47
   Google Scholar
• Coukell AJ, Spencer CM, Benfield P. Amisulpride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs 1996;6:237–56
   Web of Science ®Google Scholar
• Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs 2001;61:2123–50
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Azorin M, Bottai T, Dalery J, Garreau G, Lemperiere T, Lisoprawski A, Petitjean F, Vanelle JM. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology. 2001;44:41–6
   PubMed Web of Science ®Google Scholar
• Carrière P, Bonhomme D, Lempérière T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000;15:321–9
   PubMed Web of Science ®Google Scholar
• Chabannes JP, Pelissolo A, Farah S, Gerard D. Evaluation of the efficacy and safety of amisulpride in the treatment of schizophrenia. L’Encéphale 1998;14:386–92
   Google Scholar
• Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology 1997;132:396–401
   PubMed Web of Science ®Google Scholar
• Peuskens J, Bech P, Möller H-J, Bale R, Fleurot O, Rein W. Amisulpride versus risperidone in the treatment of acute exacerbations of schizophrenia. Psychiatry Res 1999;88:107–17
   PubMed Web of Science ®Google Scholar
• Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol. The Amisulpride Study Group. Acta Psychiatr Scand 1998;98:65–72
   PubMed Web of Science ®Google Scholar
• Wetzel H, Gründer G, Hillert A, Philipp M, Gattaz WF, Sauer H, et al. Amisulpride versus flupenthixol in schizophrenia with predominantly positive symptomatology – a double-blind controlled study comparing a selective D2-like antagonist to a mixed D1-/D2-like agonist. Psychopharmacology 1998;137:223–32
   PubMed Web of Science ®Google Scholar
• Colonna L, Saleem P, Dondey-Nouvel L, Rein W, The Amisulpride Study Group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol 2000;15:13–22
   PubMed Web of Science ®Google Scholar
• Boyer P, Lecrubier Y, Puech AJ, Dewailly J, Aubin F. Treatment of negative symptoms in schizophrenia with amisulpride. Br J Psychiatry 1995;166:68–72
   PubMed Web of Science ®Google Scholar
• Danion J-M, Rein W, Fleurot O. Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Am J Psychiatry 1999;156:610–6
   PubMed Web of Science ®Google Scholar
• Loo H, Poirier-Littre M-F, Théron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18–22
   PubMed Web of Science ®Google Scholar
• Speller JC, Barnes TR, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride vs. haloperidol. Br J Psychiatry 1997;171:564–8
   PubMed Web of Science ®Google Scholar
• Coulouvrat C, Dondey-Nouvel L. Safety of amisulpride (Solian®): a review of 11 clinical studies. Int Clin Psychopharmacol 1999;14:209–18
   PubMed Web of Science ®Google Scholar